A federal judge in Connecticut has declined to pause the multistate antitrust litigation accusing generic-drug manufacturers of price-fixing, even as settlement discussions continue. The decision keeps one of the most closely watched coordinated state enforcement actions on an active track, preserving litigation pressure while negotiations unfold in parallel.

The case is part of the long-running generic-drug pricing litigation brought by a coalition of state attorneys general against multiple manufacturers.